4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT Stock Report

Market Cap: US$325.5m

4D Molecular Therapeutics Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

David Kirn

Chief executive officer

US$1.0m

Total compensation

CEO salary percentage65.69%
CEO tenure12yrs
CEO ownership3.6%
Management average tenure4yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 18

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Nov 24
Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

CEO Compensation Analysis

How has David Kirn's remuneration changed compared to 4D Molecular Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025n/an/a

-US$196m

Mar 31 2025n/an/a

-US$176m

Dec 31 2024US$1mUS$663k

-US$161m

Sep 30 2024n/an/a

-US$143m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$105m

Dec 31 2023US$10mUS$597k

-US$101m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$111m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$3mUS$586k

-US$107m

Sep 30 2022n/an/a

-US$105m

Jun 30 2022n/an/a

-US$102m

Mar 31 2022n/an/a

-US$81m

Dec 31 2021US$5mUS$570k

-US$71m

Sep 30 2021n/an/a

-US$67m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$60m

Dec 31 2020US$702kUS$451k

-US$57m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$61m

Mar 31 2020n/an/a

-US$54m

Dec 31 2019US$554kUS$430k

-US$49m

Sep 30 2019n/an/a

-US$35m

Jun 30 2019n/an/a

-US$21m

Mar 31 2019n/an/a

-US$15m

Dec 31 2018US$546kUS$396k

-US$10m

Compensation vs Market: David's total compensation ($USD1.01M) is below average for companies of similar size in the US market ($USD2.41M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Kirn (63 yo)

12yrs
Tenure
US$1,009,003
Compensation

Dr. David H. Kirn, M.D., serves as Director at Coagulant Therapeutics, Inc He co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013. Dr. Kirn...

Leadership Team

NamePositionTenureCompensationOwnership
John Milligan
Executive Chairman5.1yrsUS$646.81k0.21%
$ 697.0k
David Kirn
Co-Founder12yrsUS$1.01m3.55%
$ 11.6m
Fariborz Kamal
President & COO5.6yrsUS$734.61k0.013%
$ 41.4k
Theresa Janke
Co-Founder & Chief of Staff12.7yrsUS$2.70mno data
Scott Bizily
Chief Legal Officer & Corporate Secretary4yrsno data0.015%
$ 47.3k
An Song
Chief Translational Medicine Advisorless than a yearno datano data
Alan Cohen
Senior VP & Therapeutic Area Head of Pulmonologyno datano datano data
Christopher Simms
Chief Commercial Officer1yrno datano data
Julie Clark
Chief Medical Officerno datano datano data
Liansheng Zhu
Senior Vice President of Biometrics & Data Qualityno datano datano data
Karen Carothers
Controller9.1yrsno datano data
4.0yrs
Average Tenure
62yo
Average Age

Experienced Management: FDMT's management team is considered experienced (4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Milligan
Executive Chairman5.1yrsUS$646.81k0.21%
$ 697.0k
David Kirn
Co-Founder12yrsUS$1.01m3.55%
$ 11.6m
Charles Theuer
Independent Director9.8yrsUS$482.24k0.069%
$ 225.5k
Susannah Gray
Independent Director5.2yrsUS$482.24k0%
$ 0
Paul Utz
Member of Scientific Advisory Board1.8yrsno datano data
Richard Moss
Member of Scientific Advisory Board1.8yrsno datano data
Jacob Chacko
Independent Director6.5yrsUS$482.24k0%
$ 0
Shawn Tomasello
Independent Director4.8yrsUS$479.18k0%
$ 0
Amit Gaggar
Member of Scientific Advisory Board1.8yrsno datano data
Nancy Miller-Rich
Independent Director4.8yrsUS$469.74k0%
$ 0
Arshad Khanani
Chair of Ophthalmology Advisory Board1.1yrsno datano data
Noriyuki Kasahara
Member of Scientific Advisory Boardless than a yearUS$488.91kno data
4.8yrs
Average Tenure
63yo
Average Age

Experienced Board: FDMT's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/09/10 19:14
End of Day Share Price 2025/09/09 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

4D Molecular Therapeutics, Inc. is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
null nullBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research